PEG-Alkyl Nanoparticles for ICG Solubility and Stability

The patent uses plasma proteins as an intermediary carrier to bind ICG molecules, preventing their rapid elimination from circulation. This binding interaction extends the circulation time and maintains diagnostic signal strength throughout the imaging procedure.

The patent creates a composite formulation by combining ICG with plasma proteins or protein-based carriers. This composite structure leverages the circulatory properties of proteins to extend the residence time of ICG in the vascular system, thereby maintaining signal strength.

The patent introduces plasma proteins or protein-based carriers as intermediaries that interact with ICG molecules. This interaction prevents ICG aggregation by providing a stable solvation shell, thereby improving solubility while maintaining molecular stability.

The patent changes the physical-chemical parameters of the ICG formulation by combining it with proteins, which alters the solubility and aggregation characteristics. This parameter change enables ICG to remain dissolved at higher concentrations without forming aggregates.

The patent uses plasma proteins or protein-based carriers as intermediaries to prevent ICG aggregation. By maintaining ICG molecules in a dispersed, non-aggregated state through protein interaction, the fluorescent activity is preserved and enhanced.

The patent changes the physical state and interaction parameters of ICG molecules through protein binding, which prevents aggregation and maintains high fluorescent activity. This parameter change ensures that ICG remains in a form that is both stable and highly fluorescent.

The patent introduces plasma proteins or protein-based carriers as protective intermediaries that shield ICG molecules from decomposition. This protective interaction stabilizes the ICG molecules throughout the imaging procedure and storage.

The patent creates a composite formulation combining ICG with proteins, which provides enhanced stability. The protein component acts as a stabilizing agent that prevents decomposition of ICG, thereby improving solution stability and shelf life.

The patent uses plasma proteins or protein-based carriers as intermediaries to bind novel fluorescent dyes, preventing them from leaving the vascular system. This binding interaction ensures that the dyes remain retained in the vascular space while maintaining improved solubility and fluorescence properties.

The patent creates composite formulations combining novel fluorescent dyes with proteins, which provides both improved solubility/fluorescence properties and vascular retention. The protein component acts as a vascular anchor that prevents extravasation while allowing the dye to maintain its enhanced optical properties.

The patent uses plasma proteins or readily available protein-based carriers as intermediaries to extend circulation time. By utilizing naturally occurring proteins rather than requiring complex synthetic conjugates, the production cost is significantly reduced while still achieving extended circulation.

The patent employs cost-effective protein-based carriers that can be produced economically at scale. These protein carriers provide sufficient circulation extension without requiring expensive custom-synthesized conjugates, thereby reducing production costs while maintaining the desired circulation time extension.